A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern’s Simmons Cancer Center announced.
Most cancer drugs are targeted to specific organs or locations in the body. Larotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type. The research appears in The Lancet Oncology.
“In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion. When this occurs, it leads to the TRK gene being turned on when it’s not supposed to be and that causes the cells to grow uncontrollably. What’s unique about the drug is it is very selective; it only blocks TRKreceptors,” said lead author Dr. Ted Laetsch, Assistant Professor of Pediatrics and with the Harold C. Simmons Comprehensive Cancer Center.
Larotrectinib, targets TRK fusions, which can occur in many types of cancer. While the TRK fusions occur in only a small percentage of common adult cancers, they occur frequently in some rare pediatric cancers, such as infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and papillary thyroid cancer, said Dr. Laetsch, who leads the Experimental Therapeutics Program (ETP) in the Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Health in Dallas.
“Every patient with a TRK fusion-positive solid tumor treated on this study had their tumor shrink. The nearly universal response rate seen with larotrectinib is unprecedented,” Dr. Laetsch said.
Among them was 13-year-old Briana Ayala of El Paso, who aspires to a career in fashion design. In 2016, Briana was found to have a rare tumor in her abdomen wrapped around her aorta, the largest artery in the body.
Surgeons in her hometown said it would be too dangerous to operate, so her family brought Briana to Children’s Health in Dallas, where UT Southwestern Professor of Surgery Dr. Stephen Megison had to remove portions of her aorta while removing most of the tumor.
But the cancer started to grow again and no further treatments were available.
Dr. Laetsch sent her tumor for genetic testing and found that Briana’s cancer had the TRK fusion, meaning the new drug might help.
Briana enrolled in the phase 1 clinical trial of larotrectinib and began taking the drug twice a day. Within weeks her pain and the swelling in her abdomen diminished, and scans showed her tumors had shrunk significantly.
Nearly two years later, Briana is back in school and playing with her dog, Goofy, and the family’s seven parakeets. She’s also been able to pick up her sketch pad and her dreams of a New York City fashion career.
“These are the kind of amazing responses we’ve seen with larotrectinib,” said Dr. Laetsch, “and this is why I’m so excited about it.”
The results of the larotrectinib trial in adult patients – a 75 percent response rate – were published last month in the New England Journal of Medicine.
The TRK-fusion mutation can be present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors. TRK, short for tropomyosin receptor kinase, is a gene that plays a key role in brain and nervous system development and has a limited role in nervous system functions such as regulating pain in later life.
Larotrectinib belongs to a class of molecules known as kinase inhibitors, which work by cutting back on the enzymatic activity of a key cellular reaction. The selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.
Equally important, the response was long-lasting for most patients. “For some of the targeted drugs in the past, many patients responded initially, but then resistance developed quickly. To date, the response to this drug seems to be durable in most patients,” said Dr. Laetsch, who investigates the use of tumor molecular profiling to guide therapy in UT Southwestern’s Pediatric Hematology and Oncology Division.
A next step in the research is a clinical trial involving a similar drug for those patients who developed resistance. Dr. Laetsch will be the national leader for that clinical trial in children.
The Latest on: Larotrectinib
via Google News
The Latest on: Larotrectinib
- Loxo Oncology Reports Third Quarter 2018 Financial Results on November 8, 2018 at 2:45 am
Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018 LOXO-292 Registrational Data Expected in 2019 LOXO-292 NDA Submission Expected in Late 2019 Enrollment of First Patient in LOXO ... […]
- Impressive Responses, but How to Find Patients With NTRK Fusion Tumors? on November 2, 2018 at 6:23 am
MUNICH — The investigational drug larotrectinib (Bayer and Loxo), which targets neurotrophic receptor tyrosine kinase (NTRK), continues to impress with high overall response rates (ORRs) and duration ... […]
- LOXO's ESMO Update On Larotrectinib - Changing Treatment Paradigms on October 25, 2018 at 5:24 am
LOXO presented an supplementary dataset for it lead compound larotrectinib at ESMO 2018 Congress. The dataset was nearly identical to the initial data, with an ORR of 81% in patients with NTRK fusion ... […]
- Loxo, Bayer biomarker-driven drug maintains high response rates in ESMO presentation on October 22, 2018 at 9:41 am
US-based Loxo Oncology and Germany’s Bayer presented data on the drug, larotrectinib, at the European Society for Medical Oncology’s annual meeting in Munich. In 109 patients included in an efficacy a... […]
- Roche takes on Loxo, Bayer in gene-defined cancer class on October 21, 2018 at 7:12 am
Germany’s Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, on... […]
- Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types on October 21, 2018 at 2:25 am
"It is exciting to see larotrectinib deliver responses to patients in these studies with TRK fusion cancer, across different ages, tumor sites of origin, or CNS involvement," said Ulrik Lassen, M.D., ... […]
- Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types on October 21, 2018 at 2:23 am
-- Median duration of response (mDOR) in primary dataset not reached after follow-up of 17.6 months(1) -- 18 percent of patients in the primary dataset experienced complete responses (CR), with the nu... […]
- Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress on October 21, 2018 at 2:17 am
STAMFORD, Conn., Oct. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, ... […]
- Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types on October 20, 2018 at 5:00 pm
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliate... […]
via Bing News